Instil Bio, Inc. (Nasdaq: TIL) announced that its collaborator, ImmuneOnco Biopharmaceuticals, has dosed the first patient in a Phase 1b/2 clinical trial of IMM2510/SYN-2510 in combination with chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) in China. This marks a significant step in evaluating the bispecific antibody's potential in treating this challenging cancer.
Clinical Trial Details
The ImmuneOnco trial will enroll first-line NSCLC patients, with initial clinical data expected in the second half of 2025. Instil Bio plans to initiate a U.S. clinical trial of SYN-2510/IMM2510 in lung cancer, targeting first-line NSCLC patients in combination with chemotherapy, with an expected initiation in the second half of 2025, pending regulatory approvals.
IMM2510/SYN-2510: A Novel Bispecific Antibody
SYN-2510/IMM2510 is a PD-L1xVEGF bispecific antibody designed for the treatment of multiple solid tumor cancers. It differentiates itself through its VEGF trap, which binds multiple VEGF receptor ligands beyond VEGF-A. The bispecific structure leverages PD-L1 as an anchor in the tumor microenvironment (TME) and enhances antibody-dependent cellular cytotoxicity (ADCC) to direct killing of PD-L1-positive tumor cells.
Strategic Implications
"We anticipate that ImmuneOnco’s initial clinical data of IMM2510/SYN-2510 in combination with chemotherapy in patients with front-line NSCLC could be extremely valuable in advancing our development of IMM2510/SYN-2510 in NSCLC," said Bronson Crouch, CEO of Instil. "The data generated, if positive, could position us to open a potential global registrational study in front-line NSCLC."
About Instil Bio
Instil Bio is focused on developing novel therapies for solid tumor cancers. SYN-2510 is their lead asset.
